|Bid||4.0000 x 600|
|Ask||13.0000 x 100|
|Day's Range||4.1000 - 4.3500|
|52 Week Range||2.5500 - 26.9500|
|PE Ratio (TTM)||-2.01|
|Earnings Date||Aug 9, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||5.21|
CHAPEL HILL, N.C., July 20, 2017-- Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cempra, Inc. Here are 5 ETFs with the largest exposure to CEMP-US. Comparing the performance and risk of Cempra, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Chapel Hill-based Cempra (CEMP) – which has struggled to regain footing after the U.S. Food and Drug Administration did not approved its pneumonia drug solithromycin in December of last year – has disclosed in an SEC filing that, should a sale of the company ensue, its acting CEO and other C-suite executives are primed for golden parachutes. According to the filing, the company has entered into a change in control severance agreement with acting CEO Dr. David Zaccardelli and into an amended change in control severance agreement with its Chief Financial Officer Mark Hahn, Chief Medical Officer Dr. David Oldach, and Executive Vice President of Investor Relations and Corporate Communications John Bluth. The agreements come at a time when the company is reviewing strategic options , having retained Morgan Stanley as a financial advisor to assist in that effort earlier this year.